Grifols, S.A. or Travere Therapeutics, Inc.: Who Leads in Yearly Revenue?

Grifols dominates Travere in revenue growth since 2014.

__timestamp	Grifols, S.A.	Travere Therapeutics, Inc.
Wednesday, January 1, 2014	3355384000	28203205
Thursday, January 1, 2015	3934563000	99892000
Friday, January 1, 2016	4049830000	133591000
Sunday, January 1, 2017	4318073000	154937000
Monday, January 1, 2018	4486724000	164246000
Tuesday, January 1, 2019	5098691000	175338000
Wednesday, January 1, 2020	5340038000	198321000
Friday, January 1, 2021	4933118000	227490000
Saturday, January 1, 2022	6063967000	212018000
Sunday, January 1, 2023	6591977000	145238000

Cracking the code

Grifols vs. Travere: A Revenue Showdown

In the competitive landscape of the pharmaceutical industry, Grifols, S.A. and Travere Therapeutics, Inc. have been vying for dominance in yearly revenue. Since 2014, Grifols has consistently outperformed Travere, showcasing a robust growth trajectory. By 2023, Grifols' revenue surged by approximately 97% from its 2014 figures, reaching a peak of over $6.6 billion. In contrast, Travere's revenue, while growing, remains modest, peaking at around $227 million in 2021 before a slight decline. This stark contrast highlights Grifols' strategic market positioning and operational efficiency. The data underscores Grifols' dominance, with its revenue being nearly 30 times that of Travere's in 2023. As the industry evolves, these figures provide a compelling narrative of growth, strategy, and market leadership.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025